<DOC>
	<DOCNO>NCT01718613</DOCNO>
	<brief_summary>Although arginine vasopressin use additional drug refractory shock worldwide clinical practice , prospective study use first choice therapy patient cancer septic shock . The aim study ass use arginine vasopressin would effective treatment septic shock cancer patient norepinephrine , decrease composite end point mortality organ failure 28 day .</brief_summary>
	<brief_title>Vasopressin Versus Norepinephrine Management Septic Shock Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<mesh_term>Vasopressins</mesh_term>
	<mesh_term>Arginine Vasopressin</mesh_term>
	<criteria>Solid neoplasm need ICU Septic Shock accord standard criterion Younger 18 year ; Pregnancy ; Raynaud 's phenomenon , systemic sclerosis vasospastic diathesis ; Severe hyponatremia ( Na &lt; 130mEq/L ) ; Acute mesenteric ischemia ; Acute myocardial infarction ; Cardiogenic shock ; Current use vasopressor randomization Expected ICU stay less 24 hour Enrolled another study ; Refusal consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>